Terapia individualizada en carcinoma epidermoide de cabeza y cuello localmente avanzado

  1. Sánchez-Escribano Morcuende, Ricardo
  2. Ceballos Viro, Jaime
  3. Filipovich Vegas, Elena
  4. Alés Martínez, José Enrique
  5. Martín Hernández, Gonzalo
Journal:
Revista ORL

ISSN: 2444-7986,  2444-7986

Year of publication: 2013

Volume: 4

Pages: 165-174

Type: Article

DIALNET GOOGLE SCHOLAR lock_openDialnet editor

More publications in: Revista ORL

Abstract

Introduction: Locally advanced head and neck squamous cell carcinoma patients (LAHNSCC) represents a truly heterogeneous population with differences in comorbidities, primary tumor location and etiology. These are key factors in optimal treatment selection. Material and methods: An extensive literature review was made in order to identify the most relevant factor in the therapeutic decision, with special interest in induction chemotherapy as the latest and most debatable option. Results: In the therapeutic decision we have to take into account factors related to the patient, age and performance status are the most important, and others related to the tumor as stage, site of origin and etiology, between this ones l, viral subtypes (EBV and HPV) are becoming relevant in the later decades. Chemoradiotherapy is considered the gold standard treatment, supported by several randomized trials and metaanalysis. Induction chemotherapy is one of the later options appeared in the therapeutic arena, improving results in organ preservation and survival. Although a substantial increase in toxicities and lack of prospective comparisons with the standard concurrent chemoradioterapy, warrants a cautious use. Conclusions: Therapeutic choice in the LAHNSCC patient is a complex and multidimensional process, that should be carried in a specialized and multidisciplinary team that can assure the highest efficiency and security for the patient

Bibliographic References

  • Blanchard P, Bourhis J, Lacas B Posner MR, Vermorken JB, CruzHernandez JJ et al. Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 2013; 31:2854-2860,
  • Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locorregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial and relation between cetuximab induced rash and survival. Lancet Oncol 2010;11:21- 28.
  • Centro Nacional de Epidemiología, Instituto de Salud Caros III, Mortalidad por cáncer y otras causas en España, 2011. Disponible en http//:www.isciii.es. Consultado el 03-08-2013
  • Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E et al. Human papilomavirus and rising oropharigeal cáncer incidence in the United States. J.Clin Oncol 2011;29: 4294-301.
  • Cohen EEW, Kamson T, Kocherginsky M, Huang CH, Agulnik M, Mittal BB et al. DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) inducition chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J. Clin Oncol 2012;30 (Suppl, abstr 5500)
  • Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfer H, Pajak TE et al. Long term results of RTOG 91-11: A comparison of three non-surgical strategies to preserve the Larynx in patients with locally advanced larynx cancer. J. Clin Oncol 2012;31:845-852.
  • Graveland P, Golusinski PJ, Buijze M. Douma R, Sons N Kuik DJ et al Loss of heterozygosity at 9p and p53 immunopositivity in surgical margins predict local relapse in head and neck squamous cell carcinoma. Int J Cancer 2011;128:1852-1859.
  • Haddad R, O´Neill A, Robinowits G, Tishler R, Khuri F, Atkins D et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol ,Disponible en http//dx.doi.org/10.1016/S1470- 2045(13)70011-1.
  • Heath S, Willis V, Allan K, Purdie K, Harwood C Shields P et al Clinically significant Human Papilomavirus in Squamous Cell Carcinoma of the head and neck in UK practice. Clin Oncol 2012;25:18-23.
  • Hitt R, Grau J, Lopez-Pousa A Berrocal A, Garcia-Giron C, Belon J et al. Randomized tphase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorrouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) folloed by chemoradiotherapy (CRT) vs crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J.Clin Oncol 2006;24 (Suppl, abstr 5515).
  • Hitt R, López-Pousa A,Martínez-Trufero J, Escrig V, Carles J, Rizo A et al. Phase III Study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin and fluoruracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J.Clin Oncol 2005;23:8636-8645.
  • Leemans CR, Braakhuis BJM Brakenhoff RH The molecular biology of head and neck cancer. Nat rev cancer 2011;11: 9-22.
  • Lefebvre JL, Pointreau Y, Rolland F, Alfonsi M, Baudoux A, Sirc C et al. Induction chemotherapy followed by either chemoradiotherapy or bioradiotherapy for larynx preservation: The TREMPLIN randomized phase II study. J.Clin Oncol 2013;31:853-859.
  • Lin JC, Wang WY, Chen KY, Wei YH, Liang WM, Jan JS et al. Quantification of plasma Epstein-Barr Virus DNA in patients with advanced nasopharyngeal carcinoma. N.Eng.J.Med 2004;350:2461-70.
  • Pathology and genetics of head and neck tumors. In: World Health Organization Classification of Tumours, Barnes L, Eveson JW, Reichart P, Sidransky D (Eds), IARC Press, Lyon 2005
  • Pignon JP, Le Maitre A, Bourhis J on behalf of the MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACHNC) an update. Int J Radiat Oncol Biol Phys 2007; 69 (2): Suppl, pp S112- S114.
  • Pignon JP, Le Maitre A, Maillard E. Borhuis J on behalf of the MACH-NC collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17346 patients. Radioter and Oncol 2009;92: 4-14.
  • Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, Todochaux J, et al. Randomized trial of induction chemotherapy with cisplatin an 5-fluorouracil with or without docetaxel for larynx preservation. J. Natl Cancer Inst 2009;101:498-506.
  • Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V et al. Cisplatin and fluorouracil alone or with docetaxel in Head and Neck cancer. N.Engl.J.Med 2007;357: 1705-1715.
  • Posner MR, Lorch JH, Goloubeva O, Tan M, Schumaker LM, Sarlis NJ et al. Survival and human papilomavirus in oropharynx cancer in TAX324: a subset analysis froma n international phase III trial. Ann Oncol 2011;22:1071-1077.
  • Vermorken JB, Remenar E, Van Herpen C, Gorlia T, Messia R, Degardin M. Cisplatin, Fluorouracil and docetaxel in unresectable Head and Neck cancer. N.Engl J Med 2007;357:1695-704.
  • Worden FP, Moyer J, Lee JS, Taylor JMG, Urba SG, Eisbruch A et al. Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngoscope 2009;119:1510-1517.
Data source: Dialnet